Sprites
Mein FinanzNachrichtenJetzt AnmeldenPasswort vergessen?
Montag, 28.05.2012Börsentäglich über 11.000 News von 416 internationalen Medien
Erweiterte
Suche
Ad hoc-Mitteilungen

OXIGENE INC

0,730 Euro		+0,020
+2,82 %
WKN: A1JFK5  ISIN: US6918283051  Ticker-Symbol: OXGN  Frankfurt | 28.05.12 | 08:05 Uhr
Aktie:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OXIGENE INC Chart 1 Jahr
1-Woche-Intraday-Chart
OXIGENE INC 1-Woche-Intraday-Chart

Aktuelle News zur OXIGENE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
11.05. OXIGENE INC - 10-Q, Quarterly Report1SEC Filings
30.04. OXiGENE (OXGN) Offers Results Showing Median, One-Year Survival Improvement in Thyroid Cancer Patients Using ZYBRESTAT and Chemo3StreetInsider.com
28.03. OXIGENE INC - 10-K, Annual Report4SEC Filings
07.02. Biotech Sector Shows No Signs of Slowing -- OXiGENE and Generex Poised for Growth / The Paragon Report Provides Equity Research on OXiGENE & Generex Biotechnology56MarketWire
NEW YORK, NY -- (Marketwire) -- 02/07/12 -- Biotech stocks are on fire in 2012. The iShares NASDAQ Biotechnology index is up more than 15 percent year-to-date as impressive earnings results have boosted...
Mehr lesen zu:
Biotech Sector Shows No Signs of Slowing -- OXiGENE and Generex Poised for Growth / The Paragon Report Provides Equity Research on OXiGENE & Generex Biotechnology
12.12. OXiGENE (OXGN), Azanta Danmark Enter ZYBRESTAT Partnership in Europe, Canada5StreetInsider.com
07.12. OXiGENE (OXGN) Reports ZYBRESTAT Missed Primary Objective in Favor Phase 27StreetInsider.com
05.12. Marina Biotech and OXiGENE Supported by Strong Clinical Programs / The Paragon Report Provides Equity Research on Marina Biotech & OXiGENE37MarketWire
NEW YORK, NY -- (Marketwire) -- 12/05/11 -- Despite a volatile market, the biotechnology industry has performed admirably in recent months. In November the sector was supported by victories with encouraging...
Mehr lesen zu:
Marina Biotech and OXiGENE Supported by Strong Clinical Programs / The Paragon Report Provides Equity Research on Marina Biotech & OXiGENE
7 Nachrichten in den letzten 6 Monaten